Unknown

Dataset Information

0

Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis.


ABSTRACT: Given the availability and efficacy of the mobilizing agent plerixafor in augmenting hematopoietic progenitor cell mobilization with granulocyte colony-stimulating factor (G-CSF), there is a strong case for comparing the cost-effectiveness of mobilization with G-CSF + cyclophosphamide versus G-CSF alone. This study investigated the cost and effectiveness (i.e., successful 4 million-CD34+ collection) of G-CSF alone versus high-dose cyclophosphamide (4 g/m2) + G-CSF mobilization (± on-demand plerixafor) in patients with multiple myeloma (MM) eligible for autograft in Italy. A decision tree-supported cost-effectiveness analysis (CEA) model in MM patients was developed from the societal perspective. The CEA model compared G-CSF alone with cyclophosphamide 4 g/m2 + G-CSF (± on-demand plerixafor) and was populated with demographic, healthcare and non-healthcare resource utilization data collected from a questionnaire administered to six Italian oncohematologists. Costs were expressed in Euro (€) 2019. The CEA model showed that G-CSF alone was strongly dominant versus cyclophosphamide + G-CSF ( ± on-demand plerixafor), with incremental savings of €1198.59 and an incremental probability of a successful 4 million-CD34+ apheresis (+0.052). Sensitivity analyses confirmed the robustness of the base-case results. In conclusion, chemotherapy-free mobilization (± on-demand plerixafor) is a "good value for money" option for MM patients eligible for autograft.

SUBMITTER: Lazzaro C 

PROVIDER: S-EPMC8338551 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis.

Lazzaro Carlo C   Castagna Luca L   Lanza Francesco F   Laszlo Daniele D   Milone Giuseppe G   Pierelli Luca L   Saccardi Riccardo R  

Bone marrow transplantation 20210322 8


Given the availability and efficacy of the mobilizing agent plerixafor in augmenting hematopoietic progenitor cell mobilization with granulocyte colony-stimulating factor (G-CSF), there is a strong case for comparing the cost-effectiveness of mobilization with G-CSF + cyclophosphamide versus G-CSF alone. This study investigated the cost and effectiveness (i.e., successful 4 million-CD34<sup>+</sup> collection) of G-CSF alone versus high-dose cyclophosphamide (4 g/m<sup>2</sup>) + G-CSF mobilizat  ...[more]

Similar Datasets

| S-EPMC8378276 | biostudies-literature
| S-EPMC7649636 | biostudies-literature
| S-EPMC11464886 | biostudies-literature
| S-EPMC6995780 | biostudies-literature
| S-EPMC3946357 | biostudies-literature
| S-EPMC4399231 | biostudies-other
| S-EPMC8114895 | biostudies-literature
| S-EPMC9924840 | biostudies-literature
| S-EPMC4548821 | biostudies-literature
| S-EPMC3065558 | biostudies-other